Braveheart Bio (BRVE)
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other se...
- Open
- 27.490
- High
- 28.095
- Low
- 27.120
- Prev. Close
- 27.420
- Volume
- 130.49K
- Turnover
- 3.58M
- Avg Price
- 27.469
- Bid/Ask Ratio
- -46.52%
- Amplitude
- 3.56%
- 52wk High
- 32.000
- Volume Ratio
- 0.00
- Turnover Ratio
- 20.38%
News
- prnewswire · 2 days ago, 06:48 AM
07:46 ETHengrui Pharma Reports 2026 Interim Results as Innovation and Globalization Continue to Drive Business Momentum
- TradingView · Aug 14 at 04:06 PM
AH Bio Fund IV Discloses Investment at Braveheart Bio with 11.4% Stake
- PUBT · Aug 14 at 04:05 PM
Braveheart Bio director Vineeta Agarwala files initial beneficial ownership statement
- PUBT · Aug 11 at 04:28 PM
OrbiMed Advisors acquires 1.940.000 Braveheart Bio common shares worth $ 34,92 juta
- RenaissanceCapital · Aug 9 at 11:00 AM
US IPO Weekly Winners & Losers
- Global Report · Aug 9 at 04:12 AM
Dutch Bros' $105M Acquisition and Nextpower's Expansion Underscore Shifting Dynamics in Niche US Equities
